Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

Charles P, Terrier B, Perrodeau É, Cohen P, Faguer S, Huart A, Hamidou M, Agard C, Bonnotte B, Samson M, Karras A, Jourde-Chiche N, Lifermann F, Gobert P, Hanrotel-Saliou C, Godmer P, Martin-Silva N, Pugnet G, Matignon M, Aumaitre O, Viallard JF, Maurier F, Meaux-Ruault N, Rivière S, Sibilia J, Puéchal X, Ravaud P, Mouthon L, Guillevin L; French Vasculitis Study Group.

Ann Rheum Dis. 2018 Aug;77(8):1143-1149. doi: 10.1136/annrheumdis-2017-212878. Epub 2018 Apr 25. Erratum in: Ann Rheum Dis. 2019 Sep;78(9):e101.

PMID:
29695500
2.

PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis.

Cornec-Le Gall E, Audrézet MP, Renaudineau E, Hourmant M, Charasse C, Michez E, Frouget T, Vigneau C, Dantal J, Siohan P, Longuet H, Gatault P, Ecotière L, Bridoux F, Mandart L, Hanrotel-Saliou C, Stanescu C, Depraetre P, Gie S, Massad M, Kersalé A, Séret G, Augusto JF, Saliou P, Maestri S, Chen JM, Harris PC, Férec C, Le Meur Y.

Am J Kidney Dis. 2017 Oct;70(4):476-485. doi: 10.1053/j.ajkd.2017.01.046. Epub 2017 Mar 27.

3.

Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis.

Puéchal X, Pagnoux C, Perrodeau É, Hamidou M, Boffa JJ, Kyndt X, Lifermann F, Papo T, Merrien D, Smail A, Delaval P, Hanrotel-Saliou C, Imbert B, Khouatra C, Lambert M, Leské C, Ly KH, Pertuiset E, Roblot P, Ruivard M, Subra JF, Viallard JF, Terrier B, Cohen P, Mouthon L, Le Jeunne C, Ravaud P, Guillevin L; French Vasculitis Study Group.

Arthritis Rheumatol. 2016 Mar;68(3):690-701. doi: 10.1002/art.39450.

4.

Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis.

Seret G, Cañas F, Pougnet-Di Costanzo L, Hanrotel-Saliou C, Jousse-Joulin S, Le Meur Y, Saraux A, Valeri A, Putterman C, Youinou P, Rojas-Villarraga A, Anaya JM, Renaudineau Y.

J Autoimmun. 2015 Jul;61:54-61. doi: 10.1016/j.jaut.2015.05.009. Epub 2015 Jun 10.

PMID:
26071203
5.

[Prospective study of drug-induced interstitial nephritis in eleven French nephrology units].

Leven C, Hudier L, Picard S, Longuet H, Lorcy N, Cam G, Boukerroucha Z, Dolley-Hitze T, Le Cacheux P, Halimi JM, Cornec Le Gall E, Hanrotel-Saliou C, Arreule A, Massad M, Duveau A, Couvrat-Desvergnes G, Renaudineau E.

Presse Med. 2014 Nov;43(11):e369-76. doi: 10.1016/j.lpm.2014.03.032. Epub 2014 Sep 11. French.

PMID:
25218248
6.

CTX-M-93, a CTX-M variant lacking penicillin hydrolytic activity.

Djamdjian L, Naas T, Tandé D, Cuzon G, Hanrotel-Saliou C, Nordmann P.

Antimicrob Agents Chemother. 2011 May;55(5):1861-6. doi: 10.1128/AAC.01656-10. Epub 2011 Feb 22.

7.

Glomerular antibodies in lupus nephritis.

Hanrotel-Saliou C, Segalen I, Le Meur Y, Youinou P, Renaudineau Y.

Clin Rev Allergy Immunol. 2011 Jun;40(3):151-8. doi: 10.1007/s12016-010-8204-4. Review.

PMID:
20414746
8.

IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation.

Garaud S, Le Dantec C, Jousse-Joulin S, Hanrotel-Saliou C, Saraux A, Mageed RA, Youinou P, Renaudineau Y.

J Immunol. 2009 May 1;182(9):5623-32. doi: 10.4049/jimmunol.0802412.

9.

[Oedema of the lower limbs].

Cledes J, Hanrotel-Saliou C, Jobic Y.

Rev Prat. 2004 Mar 31;54(6):675-80. French. No abstract available.

PMID:
15222623
10.

[Symptomatic treatment of nephrotic syndrome].

Clèdes J, Perrichot R, Hanrotel-Saliou C.

Presse Med. 2000 Mar 4;29(8):430-8. Review. French.

PMID:
10738512

Supplemental Content

Loading ...
Support Center